Clinical Trial Update: CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update exploring belatacept as a transient replacement for calcineurin inhibitors from 3 to 12 months after transplantation in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Chronic Kidney Failure

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: Nantes University Hospital | Conditions: Chronic Kidney Failure | Phase 3 | Status: UNKNOWN